Biopelle
- Company typePrivate
- Founded2005
- HeadquartersFerndale, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
Biopelle firmographics
Firmographics- Name
- Biopelle
- Legal name
- Biopelle
- Website
- https://biopelle.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Biopelle industry classification
Industry- Product category
- Professional Clinical Skincare
- NAICS
- Cosmetics, Beauty Supplies, and Perfume Retailers (456120), Health and Personal Care Retailers (456)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Treatment Skincare (Serums, Actives, Acne & Anti-aging) (CRABAAAB)
- akta.pro secondary industries
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Professional Skincare & Facial Treatments (CRABALAF), Sensitive Skin & Barrier Repair (CRABAAAG), Eye & Lip Skincare (CRABAAAC)
Keywords
Where Biopelle is headquartered
LocationHeadquarters
- HQ city
- Ferndale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biopelle business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel
Revenue model
- Direct-to-Consumer E-commerce Sales: Products sold directly to consumers through the Biopelle e-commerce website (biopelle.com/shop). Consumers purchase individual products or curated skincare sets. Revenue is generated through one-time product purchases with no subscription model mentioned.
- Professional Distribution: Products distributed through licensed skincare professionals including dermatologists, physician offices, and med-spas. Over 1,500 distribution points in North America and Australia. Professionals recommend and sell products directly to patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Retriderm Serum Mild (0.5% retinol) - $84.00 |
| One time/ perpetual license | Pay-as-you-go | Retriderm Serum Plus (0.75% retinol) - $89.50 |
| One time/ perpetual license | Pay-as-you-go | Retriderm Serum Max (1% retinol) - $94.50 |
| One time/ perpetual license | Pay-as-you-go | Tensage Intensive Serum 40 - $149.60 |
| One time/ perpetual license | Pay-as-you-go | Tensage Intensive Serum 50 - $195.00 |
| One time/ perpetual license | Pay-as-you-go | Emepelle Serum - $175.00 (currently sold out) |
| One time/ perpetual license | Pay-as-you-go | Emepelle Eye Cream - $98.00 |
| One time/ perpetual license | Pay-as-you-go | Brighten Antioxidant CE Plus Serum - $126.00 |
| One time/ perpetual license | Pay-as-you-go | Biopelle Tinted Facial Sunscreen SPF 30 - $55.00 |
| One time/ perpetual license | Pay-as-you-go | Biopelle Hydragel Eye Patches - $4.75 |
| One time/ perpetual license | Pay-as-you-go | Pre-Procedure Set - $221.40 (reg. $295.20) |
| One time/ perpetual license | Pay-as-you-go | Post-Procedure Set - $226.50 (reg. $302.00) |
| One time/ perpetual license | Pay-as-you-go | Growth Factor Anti-Aging System - $265.12 (reg. $353.50) |
| One time/ perpetual license | Pay-as-you-go | Growth Factor and Stem Cell Advanced Anti-Aging System - $378.75 (reg. $505.00) |
| One time/ perpetual license | Pay-as-you-go | Estrogen Deficient Skin Set - $351.00 (reg. $468.00) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Biopelle product offering
Product offeringCore offering
Biopelle develops, manufactures, and sells clinically-proven, professional-grade skincare products including anti-aging retinol serums, growth factor and stem cell treatments, non-hormonal menopause skincare, vitamin C brightening serums, and sunscreen/eye care specialty items. The company sells its products both directly to consumers through biopelle.com and through a network of more than 1,500 dermatologists, physician offices, and med-spas across North America and Australia. Core proprietary platforms include SCA Biorepair Technology, CellPro Technology, MEP Technology, and aqueous suspended retinol delivery.
Product overview
Biopelle is a professional-grade skincare brand offering clinically-proven, dermatology-backed skincare products through licensed providers. The product portfolio is organized into five main collections: Retriderm (retinol-based anti-aging serums in three strengths: 0.5%, 0.75%, and 1%), Tensage (growth factor and stem cell technology products including serums, eye creams, moisturizers, and cleansers), Emepelle (patented MEP Technology for non-hormonal Estrogen Deficient Skin treatment targeting menopause-related aging), Brighten (Vitamin C and AHA-based brightening and exfoliating products), and Specialty (sunscreen, eye patches, and exfoliating cleansers). The company also offers curated skincare sets for specific concerns (anti-aging, sensitive skin, pre/post-procedure care). Key proprietary technologies include SCA Biorepair Technology (snail secretion-derived growth factors), CellPro Technology (snail egg extract with signaling proteins), and MEP Technology (patented non-hormonal solution for estrogen-deficient skin). Products are distributed through over 1,500 physician offices and med-spas throughout North America and Australia.
Differentiator
Problem solved
Functional benefit
Brands
- Tensage: A collection featuring CellPro and SCA Biorepair Technology with growth factors and stem cell technology for skin rejuvenation.
- Retriderm
- Emepelle
- Brighten
- Specialty
Quantifiable outcome
- 41% improvement in wrinkles
- +8 more outcomes
Companies that use Biopelle
Customer profileSegments3 records
Ideal customer profiles3 records
Biopelle technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biopelle partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
Biopelle competitors and assessment
Company assessmentDirect peers
- SkinCeuticals: SkinCeuticals (owned by L'Oréal) sells clinically-proven, dermatologist-dispensed skincare serums and anti-aging treatments including retinol, vitamin C, and growth-factor products. Directly comparable to Biopelle in channel strategy (physician offices), proprietary actives, and premium anti-aging positioning.
- SkinMedica: SkinMedica (owned by Allergan/AbbVie) distributes physician-dispensed skincare with growth factor, retinol, and anti-aging lines. Closely matches Biopelle's professional-channel GTM, clinical-evidence-based positioning, and Tensage growth-factor portfolio.
- Obagi Medical: Obagi sells physician-dispensed clinical skincare systems for anti-aging, hyperpigmentation, and transformative skincare. Comparable to Biopelle in professional channel distribution, premium pricing, and clinically-validated anti-aging formulations.
- Alastin Skincare: Alastin (now part of Galderma) specializes in procedure-support skincare (pre/post-procedure) and TriHex Technology-backed anti-aging serums. Highly comparable to Biopelle's Pre/Post-Procedure Sets and growth-factor Tensage line.
- iS Clinical: iS Clinical sells clinically-active skincare through physicians, med-spas, and DTC, with active-ingredient serums targeting aging and acne. Directly comparable to Biopelle in distribution channels, premium actives, and clinical positioning.
- PCA Skin: PCA Skin (Colgate-Palmolive) sells professional-grade chemical peels, retinol treatments, and clinical skincare through licensed estheticians and physicians. Comparable to Biopelle in pro-channel exclusivity and clinical-skincare positioning.
- Colorescience: Colorescience is a mineral-based, dermatologist-recommended skincare and sun protection brand sold through physician offices and DTC. Highly comparable to Biopelle's Specialty line (Tinted Facial Sunscreen SPF 30) and physician-channel distribution.
- EltaMD: EltaMD (Colgate-Palmolive) is the leading dermatologist-recommended sunscreen brand sold primarily through physician offices. Comparable to Biopelle in physician-channel exclusivity, sun-protection category, and clinical-credibility positioning.
Broad incumbents
- Dermalogica: Dermalogica is a broad, established professional skincare brand sold through licensed skin therapists, spas, and DTC with a wide portfolio. Comparable to Biopelle in professional channel focus and clinically-active formulations, but at significantly larger scale and broader portfolio breadth.
Emerging players
- Allies of Skin: Allies of Skin is a clinical-grade skincare brand with growth factor and peptide-led serums sold DTC and through select professional channels. Comparable to Biopelle's Tensage line and clinically-validated actives, but with a more digital-native, DTC-led GTM.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Biopelle social profiles
Digital presenceBiopelle financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biopelle leadership team
Management profileNumber of profiles
Biopelle funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biopelle M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biopelle
What does Biopelle do?
Biopelle develops, manufactures, and sells clinically-proven, professional-grade skincare products including anti-aging retinol serums, growth factor and stem cell treatments, non-hormonal menopause skincare, vitamin C brightening serums, and sunscreen/eye care specialty items. The company sells its products both directly to consumers through biopelle.com and through a network of more than 1,500 dermatologists, physician offices, and med-spas across North America and Australia. Core proprietary platforms include SCA Biorepair Technology, CellPro Technology, MEP Technology, and aqueous suspended retinol delivery.
Is Biopelle a public or private company?
Biopelle is a private company. It is classified as unknown and is currently operating.
When was Biopelle founded?
Biopelle was founded in 2005. It employs 11 to 50 people.
Where is Biopelle based?
Biopelle is headquartered in Ferndale, United States, in the North America region.
How does Biopelle make money?
Two revenue lines are on record. Direct-to-Consumer E-commerce Sales are the primary driver. The others are professional Distribution.
Who are Biopelle's main competitors?
Direct peers on record are SkinCeuticals, SkinMedica, Obagi Medical, Alastin Skincare, iS Clinical, PCA Skin, Colorescience and EltaMD. Dermalogica is listed as a broad incumbent. Allies of Skin is listed as an emerging player.
Does Biopelle have an API?
No public API is recorded for Biopelle.
What industry is Biopelle in?
Biopelle's product category is Professional Clinical Skincare. Its primary akta.pro industry code is CRABAAAB, Treatment Skincare (Serums, Actives, Acne & Anti-aging), with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 456120 and its SIC code is 2844.